Bernick Brian 4
4 · TherapeuticsMD, Inc. · Filed Dec 14, 2018
Insider Transaction Report
Form 4
Bernick Brian
Director
Transactions
- Exercise/Conversion
Common Stock
2018-12-12$0.10/sh+91,400$9,305→ 6,648,771 total(indirect: By BF Investment Enterprises, Ltd.) - Sale
Common Stock
2018-12-12$4.18/sh−91,400$381,961→ 6,557,371 total(indirect: By BF Investment Enterprises, Ltd.) - Exercise/Conversion
Common Stock
2018-12-13$0.10/sh+91,910$9,356→ 6,649,281 total(indirect: By BF Investment Enterprises, Ltd.) - Sale
Common Stock
2018-12-13$4.12/sh−91,910$378,577→ 6,557,371 total(indirect: By BF Investment Enterprises, Ltd.) - Gift
Common Stock
2018-12-07−190,000→ 52,000 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2018-12-12−91,400→ 91,910 total(indirect: By BF Investment Enterprises, Ltd.)Exercise: $0.10From: 2012-01-01Exp: 2019-01-01→ Common Stock (91,400 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2018-12-13−91,910→ 0 total(indirect: By BF Investment Enterprises, Ltd.)Exercise: $0.10From: 2012-01-01Exp: 2019-01-01→ Common Stock (91,910 underlying)
Holdings
- 3,000(indirect: By LLC)
Common Stock
Footnotes (5)
- [F1]The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- [F2]The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.075 to $4.32, inclusive. The Reporting Person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.04 to $4.25, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The reported securities are held by the GP. As disclosed in footnote 1 above, the Reporting Person, together with his spouse as tenants by the entirety, holds a 70.6% membership interest in the GP. The Reporting Person disclaims beneficial ownership of the reported securities held by the GP, except to the extent of his pecuniary interest therein.